Considering the lag time between effective insulin titration and resulting improvement in HbA1c, the most plausible explanation for the lower HbA1c observed with detemir at the end of trial is that it can be titrated more aggressively than NPH without unacceptable risk of hypoglycaemia. Here, INS is linked to Hypoglycemia.